GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain

ACS Medicinal Chemistry Letters

Volumn 7, Issue 6, 2016, Pages 552-557

  Bamborough, Paul ^a   Barnett, Heather A ^a   Becher, Isabelle ^b,e   Bird, Mark J ^a   Chung, Chun Wa ^a   Craggs, Peter D ^a   Demont, Emmanuel H ^a   Diallo, Hawa ^a   Fallon, David J ^a,c   Gordon, Laurie J ^a   Grandi, Paola ^b   Hobbs, Clare I ^a   Hooper Greenhill, Edward ^a   Jones, Emma J ^a   Law, Robert P ^a,c   Le Gall, Armelle ^a   Lugo, David ^a   Michon, Anne Marie ^b   Mitchell, Darren J ^a   Prinjha, Rab K ^a   Sheppard, Robert J ^a,d   Watson, Allan J B ^c   Watson, Robert J ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (Germany)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

BET; BRD1; bromodomain; BRPF1; BRPF2; BRPF3; chemical probe; epigenetics; inhibitor

Indexed keywords

BROMODOMAIN INHIBITOR; GSK 6853; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SOLUBILITY; ENZYME INHIBITION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

EID: 84974652519     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00092     Document Type: Article

References (24)

1. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231 10.1016/j.cell.2012.02.013
2. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123 10.1038/nature09589
3. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La, T. N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073 10.1038/nature09504
4. Chung, C.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J. M.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clement, C. A.; Boullay, A. B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains J. Med. Chem. 2011, 54, 3827-3838 10.1021/jm200108t
5. Garnier, J. M.; Sharp, P. P.; Burns, C. J. BET bromodomain inhibitors: a patent review Expert Opin. Ther. Pat. 2014, 24, 185-199 10.1517/13543776.2014.859244
6. Mirguet, O.; Gosmini, R.; Toum, J.; Clement, C. A.; Barnathan, M.; Brusq, J.; Mordaunt, J. E.; Grimes, R. M.; Crowe, M.; Pineau, O.; Ajakane, M.; Daugan, A.; Jeffrey, P.; Cutler, L.; Haynes, A. C.; Smithers, N. N.; Chung, C.; Bamborough, P.; Uings, I. J.; Lewis, A.; Witherington, J.; Parr, N.; Prinjha, R. K.; Nicodeme, E. Discovery of epigenetic regulator I-BET762: Lead optimization to afford a clinical candidate inhibitor of the BET bromodomains J. Med. Chem. 2013, 56, 7501-7515 10.1021/jm401088k
7. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 2014, 13, 337-356 10.1038/nrd4286
8. Muller, S.; Knapp, S. Discovery of BET bromodomain inhibitors and their role in target validation MedChemComm 2014, 5, 288-296 10.1039/c3md00291h
9. Chung, C.; Tough, D. Bromodomains: a new target class for small molecule drug discovery Drug Discovery Today: Ther. Strategies 2012, 9, e111-e120 10.1016/j.ddstr.2011.12.002
10. Carlson, S.; Glass, K. C. The MOZ Histone Acetyltransferase in Epigenetic Signaling and Disease J. Cell. Physiol. 2014, 229, 1571-1574 10.1002/jcp.24617
11. Ullah, M.; Pelletier, N.; Xiao, L.; Zhao, S. P.; Wang, K.; Degerny, C.; Tahmasebi, S.; Cayrou, C.; Doyon, Y.; Goh, S. L.; Champagne, N.; Cote, J.; Yang, X. J. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes Mol. Cell. Biol. 2008, 28, 6828-6843 10.1128/MCB.01297-08
12. Poplawski, A.; Hu, K.; Lee, W.; Nateson, S.; Peng, D.; Carlson, S.; Shi, X.; Balaz, S.; Markley, J. L.; Glass, K. C. Molecular insights into recognition of N-terminal histone modifications by the BRPF1 bromodomain J. Mol. Biol. 2014, 426, 1661-1676 10.1016/j.jmb.2013.12.007
13. Qin, S.; Jin, L.; Zhang, J.; Liu, L.; Ji, P.; Wu, M.; Wu, J.; Shi, Y. Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF) J. Biol. Chem. 2011, 286, 36944-36955 10.1074/jbc.M111.244400
14. Laue, K.; Daujat, S.; Crump, J. G.; Plaster, N.; Roehl, H. H.; Kimmel, C. B.; Schneider, R.; Hammerschmidt, M. The multidomainprotein BRPF1 binds histones and is required for Hox gene expressionand segmental identity Development 2008, 135, 1935-1946 10.1242/dev.017160
15. 3 recognition by the PWWP domain of Brpf1 Nat. Struct. Mol. Biol. 2010, 17, 617-619 10.1038/nsmb.1797
16. Young, R. J.; Green, D. V. S.; Luscombe, C. N.; Hill, A. P. getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity Drug Discovery Today 2011, 16, 822-830 10.1016/j.drudis.2011.06.001
17. Demont, E. H.; Bamborough, P.; Chung, C.; Craggs, P. D.; Fallon, D.; Gordon, L. J.; Grandi, P.; Hobbs, C. I.; Hussain, J.; Jones, E. J.; Le Gall, A.; Michon, A.; Mitchell, D. J.; Prinjha, R. K.; Roberts, A. D.; Sheppard, R. J.; Watson, R. J. 1,3-Dimethyl Benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain ACS Med. Chem. Lett. 2014, 5, 1190-1195 10.1021/ml5002932
18. Palmer, W. S.; Poncet-Montange, G.; Liu, G.; Petrocchi, A.; Reyna, M.; Subramanian, G.; Theroff, J.; Yau, A.; Kost-Alimova, M.; Bardenhagen, J. P.; Leo, E.; Shepard, H. E.; Tieu, T. N.; Shi, X.; Zhan, Y.; Zhao, S.; Draetta, G.; Toniatti, C.; Jones, P.; Do, M. G.; Andersen, J. N. Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor J. Med. Chem. 2016, 59, 1440-1454 10.1021/acs.jmedchem.5b00405
19. Bennett, J.; Fedorov, O.; Tallant, C.; Monteiro, O.; Meier, J.; Gamble, V.; Savitsky, P.; Nunez-Alonso, G. A.; Haendler, B.; Rogers, C.; Brennan, P. E.; Muller, S.; Knapp, S. Discovery of a chemical tool inhibitor targeting the bromodomains of TRIM24 and BRPF1 J. Med. Chem. 2016, 59, 1642-1647 10.1021/acs.jmedchem.5b00458
20. Epigenetics Probes Collection. http://www.thesgc.org/chemical-probes/epigenetics (see PFI-4, OF-1, and NI-57).
21. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9997-10002 10.1073/pnas.96.18.9997
22. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
23. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857 10.1021/jm00145a002
24. Deplus, R.; Delatte, B.; Schwinn, M. K.; Defrance, M.; Mendez, J.; Murphy, N.; Dawson, M. A.; Volkmar, M.; Putmans, P.; Calonne, E.; Shih, A. H.; Levine, R. L.; Bernard, O.; Mercher, T.; Solary, E.; Urh, M.; Daniels, D. L.; Fuks, F. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS EMBO J. 2013, 32, 645-655 10.1038/emboj.2012.357